Phase 4Terminated
Efficacy and Safety of NVX-CoV2705 (COVID-19)
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19
- Sponsor
- Novavax (Industry)
- Enrollment
- 6,500 enrolled
- Conditions
- COVID-19; Sars-CoV-2 Infection
- Interventions
- NVX-CoV2705; Placebo
- Ages
- adults, older adults
- Registry
- NCT07086222
Full record on ClinicalTrials.gov
From the registry
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
Primary outcomes
- First episode of PCR-positive symptomatic COVID 19
History
Last registry update
Primary completion
Started
Registered